Cardiol Therapeutics (NASDAQ:CRDL – Get Free Report) will likely be issuing its Q3 2026 results before the market opens on Thursday, November 12th. Analysts expect Cardiol Therapeutics to post earnings of ($0.06) per share for the quarter. Parties can find conference call details on the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Thursday, November 19, 2026 at 4:00 PM ET.
Cardiol Therapeutics (NASDAQ:CRDL – Get Free Report) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.05. On average, analysts expect Cardiol Therapeutics to post ($0.19) EPS for the current fiscal year and ($0.24) EPS for the next fiscal year.
Cardiol Therapeutics Stock Down 1.0%
NASDAQ:CRDL opened at $1.02 on Wednesday. The company has a 50-day moving average of $1.49 and a 200-day moving average of $1.30. Cardiol Therapeutics has a 52 week low of $0.88 and a 52 week high of $2.34.
Analyst Ratings Changes
CRDL has been the subject of a number of analyst reports. HC Wainwright restated a “buy” rating and set a $9.00 price target on shares of Cardiol Therapeutics in a research note on Wednesday, September 23rd. Canaccord Genuity Group increased their target price on Cardiol Therapeutics from $8.00 to $10.00 and gave the stock a “buy” rating in a report on Monday, August 17th. Wall Street Zen raised Cardiol Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Cardiol Therapeutics in a research report on Monday, September 21st. Finally, B. Riley Financial assumed coverage on Cardiol Therapeutics in a research note on Wednesday, August 26th. They issued a “buy” rating and a $11.00 price target on the stock. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $10.00.
Check Out Our Latest Stock Report on CRDL
Cardiol Therapeutics Company Profile
Cardiol Therapeutics Inc. is a clinical-stage biotechnology company focused on developing therapies for diseases of the heart and other conditions involving inflammation and fibrosis. The company’s research is centered on novel pharmaceutical treatments intended to address unmet needs in cardiovascular medicine. Cardiol’s lead investigational product, CardiolRx, is an oral formulation of pharmaceutical-grade cannabidiol. It is being evaluated as an anti-inflammatory therapy for acute myocarditis, an inflammation of the heart muscle, and recurrent pericarditis, an inflammation of the membrane surrounding the heart.
Featured Stories
- Five stocks we like better than Cardiol Therapeutics
- Why Kinder Morgan’s Chairman Just Bought $15 Million in Stock
- Rocket Lab’s Record Backlog Could Fuel a Rebound, But Neutron Raises the Stakes
- Don’t Let Their Low Yields Fool You: 3 Dividend Stocks Worth Watching
- A $4 Billion Jolt: NRG Energy Powers Data Center Ambitions
Receive News & Ratings for Cardiol Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiol Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
